|Last Price$12.72||Day Change (%)-0.08%|
|Open Price$12.72||Day Change ($)-0.01|
|Day Range12.72–12.72||52-Week Range12.12–12.80|
As of Mon 07/25/2016 | USD
Global Intravenous Equipment Strategic Business Report 2015-2022 - Smart Infusion Systems: Marking the Convergence of Healthcare IT & IV Drug Delivery Systems - Research and Markets
Federal Circuit Rules for The Medicines Company in Angiomax® (bivalirudin) Patent Litigation
Despite the high 39% premium to Hospira's stock price, we believe the acquisition price is justified based on Pfizer's ability to unlock more value with its global reach.
Welcome to Hospira's First Quarter 2014 Conference Call. All lines have been placed on listen-only mode to prevent any background noise. Following the speakers' remarks, there will be a question-and-answer period.
Four candidates stood out from their growth counterparts.